Floatz logo

TRASTUZUMAB

Refractory Chronic Myelomonocytic Leukemia

OHSU Knight Cancer Institutemonoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Refractory Chronic Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
gsk1120212
M.D. Anderson Cancer Center
Phase 2B
PREDNISONE TABLETS
Indiana University
Phase 1/2B
Calcium folinate pentahydrate
M.D. Anderson Cancer Center
Phase 1/2CCC
prt543
Prelude Therapeutics
Phase 1CC
Gdc-0449
OHSU Knight Cancer Institute
Phase 1CC

View all 38 →

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
inflammatory breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
HER2/Neu PositiveDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →